Bold health claims have been made for the power of turmeric. Is there anything in them, asks Michael Mosley.
Turmeric is a spice which in its raw form looks a bit like ginger root, but when it’s ground down you get a distinctive yellowy orange powder that’s very popular in South Asian cuisine. Until recently the place you would most likely encounter turmeric would be in chicken tikka masala, one of Britain’s most popular dishes.
These days, thanks to claims that it can improve everything from allergies to depression, it’s become incredibly trendy, not just cooked and sprinkled on food but added to drinks like tea.
Treating Diabetes And The Complications Arising From It Costs The NHS Around £10 Billion Annually
Tackling diabetes is “fundamental” to the future of NHS as the number of adults with the condition nears four million, Public Health England has warned.
Around 3.8 million adults in England now have diabetes, with at least 940,000 of those undiagnosed, new figures have revealed.
About 90 per cent of the cases are Type 2 diabetes, which is linked to being overweight and obese and therefore largely preventable, PHE, who released the data, said.
The other 10 per cent are Type 1, which usually develops in childhood and is often inherited.
Curcumin, the chemical compound found within the Indian spice turmeric, has been receiving popular press recently due to its health-promoting properties.
The trouble is that Curcumin is poorly absorbed by the body when it’s consumed by itself. But research from Indena, the world leading company in identifying, developing and producing active plant derivatives has found that when the Curcumin extract is added to a plant extract phytosome known as a phosphatidylcholine (PC), it is more readily absorbed by the body.
PC is one of the essential components found in human cells and this is why when Curcumin is added to a phytosome, it can reach the cells that need it the most.
Despite the Conservative Party having promised to increase NHS spending by £8 billion a year during this parliament – the minimum demanded by its managers – we learn of a crisis within the institution that promises a financial shortfall of £20 billion by 2020-21. Without (so far) any consultation, the NHS proposes a massive reorganisation that could include hospital closures and cuts, and these could start within months, just as the NHS suffers its winter overload.
Why have things come to this? According to Government figures, the £437 million spent in the first year of the NHS’s existence in 1948-49 is equivalent to £15 billion today.
With any kind of luck, chemotherapy’s days as one of the leading cancer treatments will be over soon. A new, revolutionary therapy is on the horizon. Researchers have announced that this breakthrough treatment would utilize the body’s own immune system to attack cancer cells — a huge improvement over toxic chemo.
Natural News reports that scientists from the Memorial Sloan Kettering Cancer Center, located in New York, claim to have successfully experimented with the new treatment. Sixteen people with advanced leukemia that had run out of alternatives volunteered to be part of their experiment and underwent what the researchers have dubbed “targeted T cell therapy.” Miraculously, the therapy actually eliminated cancerous cells in most of the patients.
Excess hospital admissions of people from poorer parts of England cost the NHS £4.8bn in a single year, according to new research.
An analysis by York University academics found there were 264,000 excess admissions from less well-off areas between April 2014 and April 2015.
The researchers said they had not found out the exact reasons behind the problem, but added that poor people were not being looked after as well as rich people by GPs.
They said this was not necessarily the fault of the doctors, but could be a systemic problem or because poorer people were not going to their local surgery for some reason.
The long-awaited revision of FDA guidance rules for new supplements is finally here. It is very bad news. Highest-level Action Alert!
We normally publish our newsletter on Tuesday, but are sending out this issue today because of its urgency.
What we are dealing with here is whether the supplement industry is allowed to innovate and create new supplements. The FDA, working as usual on behalf of the drug industry, says no. We need your help to stop this right now. It will take a huge effort on all of our parts and we need to start immediately.
Over the last few years, one of the biggest issues facing the supplement industry has been the confusion over how to comply with the new dietary ingredient (NDI) provisions contained in the landmark Dietary Supplement Health and Education Act of 1994 (DSHEA), the main law governing supplements.
It has been estimated that 14.8 million Americans suffer from major depressive disorder and of this number 6 million are elderly. If we include anxiety disorders, which commonly accompany depression, the number jumps to 40 million adults. At a cost of $44 billon dollars a year just for care of the seniors, this impacts the national budget as well.
Depression later in life tends to last longer and be more severe than at younger ages. It is also associated with a high rate of suicide.
Previously, it was thought that major depression was secondary to a deficiency in certain neurotransmitters in the brain, particularly the monoamines, which include serotonin, norepinephrine and dopamine.
A cannabidiol (CBD) vaporiser that has helped thousands of people suffering from a variety of conditions is being tested by an NHS unit, an unprecedented step that could increase scrutiny on cannabis’ medical benefits and have a huge impact on the UK’s legislation on it.
The MediPen, a legal way to consume CBD, which, unlike tetrahydrocannabinol (THC), is non-psychoactive, has been on sale for a year now and drew very positive reviews, relieving the pain of people with everything from depression and anxiety to arthritis and fibromyalgia.
The company told The Independent it has been consulting with a group of production and regulatory support pharmacists from the NHS for the past few months, who have been testing their proprietary cannabis oil formulation.
Dirty Medicine: The Handbook, is a follow-up to ‘Dirty Medicine ‘ that appeared in 1993. Anybody involved in alternative medicine will be aware of direct and also subterfuge campaigns by powerful interests against them. Obviously in a pluralistic society other viewpoints will challenge and so it should be. If somebody invents a bizarre new form of therapy this should be looked at in a sceptical manner. However this book argues that ‘scientific corporatism’ is attempting to gain complete control in an anti-democratic and sinister manner.
This book aims to give a resume of the most important players in these attacks. Read More